Clearside Biomedical Faces Delisting Notice
Ticker: CLSDQ · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1539029
| Field | Detail |
|---|---|
| Company | Clearside Biomedical, Inc. (CLSDQ) |
| Form Type | 8-K |
| Filed Date | Dec 8, 2025 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Clearside Biomedical got a delisting notice, might be moving exchanges.
AI Summary
Clearside Biomedical, Inc. filed an 8-K on December 8, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listing. The company, incorporated in Delaware, is in the pharmaceutical preparations industry.
Why It Matters
This filing indicates potential issues with Clearside Biomedical's continued listing on an exchange, which could impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading status and investor confidence.
Key Players & Entities
- Clearside Biomedical, Inc. (company) — Registrant
- December 8, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 2834 (industry_code) — Standard Industrial Classification
- 452437375 (ein) — IRS Employer Identification No.
- 001-37783 (commission_file_number) — SEC File Number
- 900 North Point Parkway Suite 200 (address) — Principal Executive Offices
- Alpharetta, Georgia 30005 (address) — Principal Executive Offices Location
- (678) 270-3631 (phone_number) — Registrant's Telephone Number
FAQ
What is the specific reason for Clearside Biomedical's notice of delisting or failure to satisfy a continued listing rule?
The filing states it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing', but does not detail the specific rule or standard not met within this 8-K summary.
When was this 8-K form filed?
The 8-K form was filed on December 8, 2025.
What is Clearside Biomedical, Inc.'s primary industry?
Clearside Biomedical, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, classified under SIC code 2834.
Where is Clearside Biomedical, Inc. headquartered?
Clearside Biomedical, Inc.'s principal executive offices are located at 900 North Point Parkway, Suite 200, Alpharetta, Georgia 30005.
What is the SEC file number for Clearside Biomedical, Inc.?
The SEC file number for Clearside Biomedical, Inc. is 001-37783.
Filing Stats: 1,080 words · 4 min read · ~4 pages · Grade level 14 · Accepted 2025-12-08 16:32:47
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value CLSD The Nasdaq Stock Mar
Filing Documents
- d98628d8k.htm (8-K) — 29KB
- 0001193125-25-311305.txt ( ) — 141KB
- clsd-20251208.xsd (EX-101.SCH) — 3KB
- clsd-20251208_lab.xml (EX-101.LAB) — 18KB
- clsd-20251208_pre.xml (EX-101.PRE) — 11KB
- d98628d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 8, 2025 CLEARSIDE BIOMEDICAL, INC. By: /s/ Charles A. Deignan Name: Charles A. Deignan Title: Chief Financial Officer